, Volume 58, Issue 2, pp 283–296 | Cite as

Management of Onychomycoses

A Review of its Use in Genital Warts
  • Markus Niewerth
  • Hans C. Korting
Disease Management


Onychomycoses, infections of the nail caused by fungi, are amongst the most common illnesses. Because of the high incidence of these infections and problemsinvolved in their therapy, they have received much attention, particularly as concerns a better characterisation of the causative micro-organisms. Onychomycosis caused by dermatophytes (tinea unguium) is most common and is found more frequently on the feet than on the hands. The clinical presentation of onychomycosis is at best indicative of fungal infection, and the growth of a credible pathogen is an indispensable prerequisite for definite diagnosis. The clinical appearance is variable. Four major types of manifestation have been characterised, depending on localisation and spread.

New antifungal agents for systemic or topical application based on novel active substances or vehicles are available, and cure is feasible for the majority of cases. Therapy can and should be individualised, depending on the characteristics of the particular case.

Currently, continuous or intermittent oral treatment with itraconazole or terbinafine exhibit a particularly favourable risk: benefit ratio. Fluconazole might become an alternative in the near future. With respect to topical treatment, ciclopirox or amorolfine lacquer and the bifonazole/urea combination deserve particular interest. However, cure cannot be expected for every case.


Adis International Limited Fluconazole Itraconazole Dermatol Terbinafine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haneke E. Therapie der Nagelmykosen. Hautarzt 1993; 44: 335–46PubMedGoogle Scholar
  2. 2.
    Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993; 129: 101–9PubMedCrossRefGoogle Scholar
  3. 3.
    Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31: S21–5PubMedCrossRefGoogle Scholar
  4. 4.
    Baran R, Badillet G. Primary onycholysis of the big toenails: a review of 113 cases. Br J Dermatol 1982; 106: 529–34PubMedCrossRefGoogle Scholar
  5. 5.
    Symonds JM, O’Dell CA. Candida nail bed infection and cosmetic acrylic extensions — potential source of hospital infection? J Hospital Infect 1993; 23: 243–4CrossRefGoogle Scholar
  6. 6.
    Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Quality Life Res 1993; 2: 341–8CrossRefGoogle Scholar
  7. 7.
    Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 Suppl. 43: 15PubMedCrossRefGoogle Scholar
  8. 8.
    Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87–9PubMedCrossRefGoogle Scholar
  9. 9.
    Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754–6PubMedCrossRefGoogle Scholar
  10. 10.
    Zaias N. Clinical manifestations of onychomycoses. Clin Exp Dermatol 1992; 17 Suppl. 1: 6–7PubMedCrossRefGoogle Scholar
  11. 11.
    Baran R, Hay RJ, Tosti A, et al. A new classification of onychomycosis. Br J Dermatol 1998; 139: 567–71PubMedCrossRefGoogle Scholar
  12. 12.
    Leyden JL. Tinea pedis: pathophysiology and treatment. J Am Acad Dermatol 1994; 31: S31–3PubMedCrossRefGoogle Scholar
  13. 13.
    Evans EGV. Nail dermatophytosis: the nature and scale of the problem. J Dermatol Treatment 1990; 1 Suppl. 2: 47–8CrossRefGoogle Scholar
  14. 14.
    Haneke E. Fungal infections of the nail. Semin Dermatol 1991; 10: 41–53PubMedGoogle Scholar
  15. 15.
    Midgley G, Moore MK, Cook JC, et al. Mycology and nail disorders. J Am Acad Dermatol 1994; 31: S68–74PubMedCrossRefGoogle Scholar
  16. 16.
    Elewski BE, Greer DL. Hendersonula toruloidea and Scytalidium hyalinum. Arch Dermatol 1991; 127: 1041–4PubMedCrossRefGoogle Scholar
  17. 17.
    Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol 1997; 136: 424–7PubMedCrossRefGoogle Scholar
  18. 18.
    Ellis DH, Watson AB, Marley J, et al. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490–3PubMedCrossRefGoogle Scholar
  19. 19.
    Gupta AK, Sibbald RG, Lynde CW et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36: 395–402PubMedCrossRefGoogle Scholar
  20. 20.
    Zienicke HC, Korting HC, Lukacs A, et al. Dermatophytosis in children and adolescents: epidemiology, clinical, and microbiological aspects changing with age. J Dermatol (Tokyo) 1991; 18: 438–46PubMedGoogle Scholar
  21. 21.
    Korting HC, Schäfer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37: 2064–8PubMedCrossRefGoogle Scholar
  22. 22.
    Dompmartin D, Dompmartin A, Deluol AM, et al. Onychomycosis and AIDS: clinical and laboratory findings in 63 patients. Int J Dermatol 1990; 29: 337–9PubMedCrossRefGoogle Scholar
  23. 23.
    Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415–29PubMedGoogle Scholar
  24. 24.
    Blecher P, Korting HC, A new combined diagnostic approach to clinically and microscopically suspected onychomycosis unproven by culture. Mycoses 1993; 36: 312–4Google Scholar
  25. 25.
    Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992; 17 Suppl. 1: 37–40PubMedCrossRefGoogle Scholar
  26. 26.
    Haneke E. Nail biopsies in onychomycosis. Mycoses 1985; 28: 473–80CrossRefGoogle Scholar
  27. 27.
    Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517–9PubMedCrossRefGoogle Scholar
  28. 28.
    Meinhof W. Isolierung und Identifizierung von Dermatophyten. Zbl Bakt 1990; 273: 229–45Google Scholar
  29. 29.
    Bastert J, Korting HC. Diagnostische Methoden zur Speziesspezifischen Differenzierung unterschiedlicher Dermatophyten. Dtsch Med Wschr 1998; 123: 499–503PubMedCrossRefGoogle Scholar
  30. 30.
    Baden HP. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch Dermatol 1994; 130: 558–9PubMedCrossRefGoogle Scholar
  31. 31.
    Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 1994; 31: S74–7PubMedCrossRefGoogle Scholar
  32. 32.
    Baran R, Hay RJ. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 1985; 10: 413–8PubMedCrossRefGoogle Scholar
  33. 33.
    Stettendorf S. Topical treatment of onychomycoses with bifonazole-urea ointment. In: Nolting S, Korting HC, editors. Onychomycoses. Berlin, Heidelberg: Springer, 1990: 102–8CrossRefGoogle Scholar
  34. 34.
    Abeck D, Gruseck E, Korting HC, et al. Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch Ärztebl 1996; 93: A–2027–32Google Scholar
  35. 35.
    Baran R, De Doncker R. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol (Stockh) 1996; 76: 82–3Google Scholar
  36. 36.
    Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911–33CrossRefGoogle Scholar
  37. 37.
    Schäfer-Korting M, Korting HC, Mutschier E. Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Eur J Clin Pharmacol 1985; 29: 351–4PubMedCrossRefGoogle Scholar
  38. 38.
    Warnock DW. New pharmacological concepts in antimycotic treatment. J Eur Acad Dermatol Venereol 1993; 2 Suppl. 1: S19–25Google Scholar
  39. 39.
    Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243–8PubMedCrossRefGoogle Scholar
  40. 40.
    Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585–620Google Scholar
  41. 41.
    Korting HC, Ollert M, Abeck D. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum. and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206–8PubMedCrossRefGoogle Scholar
  42. 42.
    Schäfer-Korting M, Korting HC, Lukacs A, et al. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol 1990; 22: 211–5PubMedCrossRefGoogle Scholar
  43. 43.
    Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263–8PubMedCrossRefGoogle Scholar
  44. 44.
    Willemsen M, De Doncker P, Willems J. Post-treatment itraconazole levels in nail. New implications for the treatment of onychomycosis. J Am Acad Dermatol 1992; 26: 731–5PubMedCrossRefGoogle Scholar
  45. 45.
    Heykants J, Van Peer A, Van de Velde V. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32: 67–87PubMedCrossRefGoogle Scholar
  46. 46.
    Grant SM, Clissold SP. Itraconazole.: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310–44PubMedCrossRefGoogle Scholar
  47. 47.
    Balfour JA, Faulds D. Terbinafine: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259–84PubMedCrossRefGoogle Scholar
  48. 48.
    Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum. onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120–3PubMedCrossRefGoogle Scholar
  49. 49.
    Nolting S, Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130 Suppl. 43: 16–21PubMedCrossRefGoogle Scholar
  50. 50.
    Niewerth M, Splanemann V, Korting HC, et al. Antimicrobial susceptibility testing of dermatophytes — comparison of the agar macrodilution and broth microdilution tests. Chemotherapy (Basel) 1998; 44: 31–5CrossRefGoogle Scholar
  51. 51.
    Schatz F, Bräutigam M, Dobrowolowski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377–83PubMedCrossRefGoogle Scholar
  52. 52.
    Finlay AY, Lever L, Thomas R, et al. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1 Suppl. 2: 51–3CrossRefGoogle Scholar
  53. 53.
    Nedelman JR, Gibiansky E, Robbins B A, et al. Pharmacokinetics and pharmacodynamics of multi-dose terbinafine. J Clin Pharmacol 1996; 36: 452–61PubMedGoogle Scholar
  54. 54.
    Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304:1151–4PubMedCrossRefGoogle Scholar
  55. 55.
    Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909–10PubMedCrossRefGoogle Scholar
  56. 56.
    Smith SW, Sealy DP, Schneider E, et al. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995; 88: 1217–20PubMedCrossRefGoogle Scholar
  57. 57.
    Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1990; 39: 877–916PubMedCrossRefGoogle Scholar
  58. 58.
    Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127–30PubMedCrossRefGoogle Scholar
  59. 59.
    Wildfeuer A, Scidl HP. The in vitro activity of fluconazole against fungi involved in dermal infections. Mycoses 1994; 37: 447–9PubMedCrossRefGoogle Scholar
  60. 60.
    Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toenails with fluconazole 150 mg once weekly. Acta Derm Venereol (Stockh) 1996; 76: 219–21Google Scholar
  61. 61.
    Suringa DW. Treatment of superficial onychomycosis with topically applied glutaraldehyde. Arch Dermatol 1970; 102: 163–76PubMedCrossRefGoogle Scholar
  62. 62.
    White MI, Clayton YM. The treatment of fungus and yeast infections of nails by the method of ‘chemical removal’. Clin Exp Dermatol 1982; 7: 273–6PubMedCrossRefGoogle Scholar
  63. 63.
    Hay RJ, Roberts DT, Doherty VR, et al. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164–7PubMedCrossRefGoogle Scholar
  64. 64.
    Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol-urea-lactic acid solution. Mycoses 1988; 32: 536–40CrossRefGoogle Scholar
  65. 65.
    Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175–7PubMedCrossRefGoogle Scholar
  66. 66.
    Haria M, Bryson HM. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycoses and other superficial fungal infections. Drugs 1995; 49: 103–20PubMedCrossRefGoogle Scholar
  67. 67.
    Nolting S, Seebacher C. Ciclopiroxolamin. Wegweiser topischer Mykose-Therapie. Frankfurt, Jena: Universitätsverlag Jena, 1993Google Scholar
  68. 68.
    Pharmaceutical Research Associates. Ciclopirox nail lacquer 8%: integrated summary of efficacy. Internal Report 1998Google Scholar
  69. 69.
    Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992; 17 Suppl. 1: 44–9PubMedCrossRefGoogle Scholar
  70. 70.
    Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 Suppl 1: 41–3CrossRefGoogle Scholar
  71. 71.
    Korting HC, Blecher P, Stallmann D, et al. Dermatophytes on the feet of HIV-infected patients: frequency, species distribution, localisation and antimicrobial susceptibility. Mycoses 1993; 36: 271–4PubMedCrossRefGoogle Scholar
  72. 72.
    Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750–3PubMedCrossRefGoogle Scholar
  73. 73.
    Hofmann H, Bräutigam M, Weidinger G. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919–22PubMedCrossRefGoogle Scholar
  74. 74.
    Haneke E, Tausch I, Bräutigam M, et al. Short duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72–7PubMedCrossRefGoogle Scholar
  75. 75.
    Goodfield MJD. Short duration therapy with terbinafine for dermatophyte onychomycosis: a multicenter trial. Br J Dermatol 1992; 126 Suppl. 39: 33–5PubMedCrossRefGoogle Scholar
  76. 76.
    Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33: 775–9PubMedCrossRefGoogle Scholar
  77. 77.
    Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol (Stockh) 1997; 77: 66–9Google Scholar
  78. 78.
    Goodfield MJD. Clinical results with terbinafine in onychomycosis. J Dermatol Treatment 1990; 1 Suppl. 2: 55–7CrossRefGoogle Scholar
  79. 79.
    Tausch I, Bräutigam M, Weidinger G, et al. Evaluations of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br J Dermatol 1997; 136: 737–42PubMedCrossRefGoogle Scholar
  80. 80.
    Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itra-conazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359–66PubMedCrossRefGoogle Scholar
  81. 81.
    Haneke E, Delescluse J, Plinck EPB, et al. The use of itra-conazole in onychomycosis. Eur J Dermatol 1996; 6: 7–10Google Scholar
  82. 82.
    Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: open and double-blind studies. Acta Denn Venereol (Stockh) 1990; 70: 137–40Google Scholar
  83. 83.
    De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180–3PubMedGoogle Scholar
  84. 84.
    Bonifaz A, Carrasco-Gerard E, Saul A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol 1997; 36: 70–2PubMedCrossRefGoogle Scholar
  85. 85.
    De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969–74PubMedCrossRefGoogle Scholar
  86. 86.
    Odom RB, Aly R, Scher RK, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997; 36: 231–5PubMedCrossRefGoogle Scholar
  87. 87.
    De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis. Arch Dermatol 1996; 132: 34–41PubMedCrossRefGoogle Scholar
  88. 88.
    Heikkilä H, Stubb S. Long-term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol (Stockh) 1997; 77: 70–1Google Scholar
  89. 89.
    Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toenail onychomycosis. Br J Dermatol 1997; 136: 230–4PubMedCrossRefGoogle Scholar
  90. 90.
    De Doncker P, Scher RK, Barab RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some non-dermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173–7PubMedCrossRefGoogle Scholar
  91. 91.
    Bräutigam M, Nolting S, Schopf RE, et al. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995; 311: 919–22PubMedCrossRefGoogle Scholar
  92. 92.
    Tosti A, Piraccini BC, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595–600PubMedCrossRefGoogle Scholar
  93. 93.
    Honeyman JF, Talarico FS, Arruda LHF, et al. Itraconazole versus terbinafine (Lamisil): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997; 9: 215–21Google Scholar
  94. 94.
    Arenas R, Dominguez-Cherit J. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138–43PubMedCrossRefGoogle Scholar
  95. 95.
    Evans EGV, Sigurgeirsson B, Billstein S. Continuous terbinafine versus intermittent itraconazole in the treatment of toenail onychomycosis (L.I.O.N. study). Focus on Fungal Infection 8; 1998 Mar 4–6; Orlando (FL)Google Scholar
  96. 96.
    Scher RK. A placebo controlled, randomized, double-blind trial of once-weekly fluconazole (150, 300, or 45 mg) in the treatment of distal subungual onychomycosis of the toenail [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, Canada; 380Google Scholar
  97. 97.
    Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115–7CrossRefGoogle Scholar
  98. 98.
    Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993; 186: 59–61PubMedCrossRefGoogle Scholar
  99. 99.
    Feuilhade M, Baran R, Goettmann S, et al. Onychomycoses dermatophytiques avec atteinte de la matrice: intérêt de l’association d’un vernis contenant 5% d’amorolfine a un traitement oral par terbinafine. Ann Dermatol 1996; 123 Suppl.: 143Google Scholar
  100. 100.
    Hann SK, Kim JB, Im S, et al. Itraconazole-induced acute hepatitis. Br J Dermatol 1993; 129: 500–1PubMedCrossRefGoogle Scholar
  101. 101.
    Rosen T. Debilitating edema associated with itraconazole therapy. Arch Dermatol 1994; 130: 260–1PubMedCrossRefGoogle Scholar
  102. 102.
    Heymann WR, Manders SM. Itraconazole-induced acute generalized exanthematic pustulosis. J Am Acad Dermatol 1995; 32: 131–2Google Scholar
  103. 103.
    Zuckerman JM, Tunkel AR. Itraconazole: a new triazole antifungal agent. Infect Control Hosp Epidemiol 1994; 15: 397–410PubMedCrossRefGoogle Scholar
  104. 104.
    Tailor SAN, Gupta AK, Walker SE, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996; 132: 350–2PubMedCrossRefGoogle Scholar
  105. 105.
    Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995; 33: 134–5PubMedCrossRefGoogle Scholar
  106. 106.
    Rzany B, Mockenhaupt M, Gehring W, et al. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol 1994; 30: 509PubMedCrossRefGoogle Scholar
  107. 107.
    Carstens J, Wendelboe P, Sogaard H, et al. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol (Stockh) 1994; 74: 391–2Google Scholar
  108. 108.
    McGregor JM, Rustin MHA. Terbinafine and erythema multi-forme. Br J Dermatol 1994; 131: 587–8PubMedCrossRefGoogle Scholar
  109. 109.
    Inman W, Kubota K, Pearce G, et al. PEM Report Number 7. Itraconazole. Pharmacoepidemiol Drug Saf 1993; 2: 423–43CrossRefGoogle Scholar
  110. 110.
    O’Sullivan DP, Needham CA, Bangs A, et al. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol 1996; 42: 559–65PubMedGoogle Scholar
  111. 111.
    Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995; 131: 937–42PubMedCrossRefGoogle Scholar
  112. 112.
    Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol 1998; 139: 747–8PubMedCrossRefGoogle Scholar
  113. 113.
    Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol 1997; 37: 979–88PubMedCrossRefGoogle Scholar
  114. 114.
    Brodell RT, Elewski BE. Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995; 33: 259–60PubMedCrossRefGoogle Scholar
  115. 115.
    Robbins B, Chang CT, Cramer JA, et al. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Therapeutics 1996; 59: 275–83CrossRefGoogle Scholar
  116. 116.
    Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; S50-4Google Scholar
  117. 117.
    Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87–90PubMedCrossRefGoogle Scholar
  118. 118.
    Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmaco-economic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35–44PubMedCrossRefGoogle Scholar
  119. 119.
    Davis R, Balfour JA. Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections. Pharmaco-Economics 1995; 8: 253–69Google Scholar
  120. 120.
    Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 Suppl. 43: 32–4PubMedCrossRefGoogle Scholar
  121. 121.
    Bergman W, Rutten FFH. Orale behandling van onychomycose van de teennagels; vergelijking van kosteneffectiviteit van griseofulvin, itraconazol, ketoconazol en terbinafine. Ned Tijdschr Geneeskd 1994; 138: 2346–50PubMedGoogle Scholar
  122. 122.
    Chren MM. Costs of therapy for dermatophyte infections. J Am Acad Dermatol 1994; 31: S103–6PubMedCrossRefGoogle Scholar
  123. 123.
    Van Doorslaer EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239–44PubMedCrossRefGoogle Scholar
  124. 124.
    Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenail. Pharmacoeconomics 1998; 13: 1–15CrossRefGoogle Scholar
  125. 125.
    Oh PI, Shear NH, Einarson TR. Cost-effectiveness analysis of antifungal therapy for onychomycosis. 1996 International Summit on Cutaneous Antifungal Therapy; 1996 May 26–28; VancouverGoogle Scholar
  126. 126.
    Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997; 19: 559–69PubMedCrossRefGoogle Scholar
  127. 127.
    Gupta AK, De Doncker P, Heenen M. An overview of assessment of the use of the antifungal agents itraconazole, terbinafine, and fluconazole in dermatology. In: Korting HC, Schäfer-Korting M, editors. The benefit/risk ratio. A handbook for the use of potentially hazardous drugs. Boca Raton (FL): CRC Press, 1999: 263–85Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Markus Niewerth
    • 1
  • Hans C. Korting
    • 1
  1. 1.Klinikum Innenstadt, Dermatologische Klinik and PoliklinikLudwig-Maximilians-UniversitätMunichGermany

Personalised recommendations